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A Bayesian approach to competing risks
analysis with masked cause of death
Ananda Sen,a Mousumi Banerjee,b∗† Yun Lib and Anne-Michelle Noonec
Cause-specific analyses under a competing risks framework have received considerable attention in the statistical literature.
Such analyses are useful for comparing mortality patterns across racial and/or age groups. Earlier work in the statistical
literature focused on the situation when the cause of death is known. A challenging twist to the problem arises
when the cause of death is not known exactly, but can be narrowed down to a set of potential causes that do
not necessarily act independently. This phenomenon, referred to as masking, is often the result of incomplete or
partial information on death certificates and/or lack of routine autopsy on every patient. In this article we propose a
semiparametric Bayesian approach for analyzing competing risks survival data with masked cause of death. The models
proposed do not assume independence among the causes, and are valid for an arbitrary number of causes. Further,
the Bayesian approach is flexible in allowing a general pattern of missingness for the cause of death. We illustrate our
methodology using breast cancer data from the Detroit Surveillance, Epidemiology, and End Results registry. Copyright
© 2010 John Wiley & Sons, Ltd.
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1. Introduction
Cause-specific analysis under a competing risks framework has received considerable attention in the statistical literature [1--3].
David and Moeschberger [4] in their seminal book introduced and integrated the theory behind the general competing risks
model. Since then numerous investigations dealing with the issues and nuances of a competing risks model have been carried
out [5--9]. Much of the earlier work in this area have focused on the situation when the exact cause of death is known.
A challenging twist to this problem arises when the cause of death is not known exactly but can be narrowed down to a set
of potential causes. This phenomenon, referred to as masking, is often the result of incomplete or partial information on death
certificates and/or lack of routine autopsy on every patient. Masked data frequently arise in population-based registries, such as
the Surveillance, Epidemiology, and End Results (SEER) cancer registry that captures incidence and mortality data on cancers in the
United States. Approximately 16 per cent of the deceased breast cancer cases in the SEER registry do not have exact information
on the underlying cause of death due to missing or partial information on the state death certificate. Thus their cause of death
is not known exactly. However, for many of these women information on related causes of death is captured in six additional
fields in SEER. The related causes of death provide a set of ‘potential’ causes that a woman could have died from. This presents
an example of masked survival data. The survival study of heart transplant patients [10] and the longitudinal study on breast
cancer patients [11] are two other illuminating examples of masked survival data available in the literature. Masked survival data
are also quite common in industrial applications [12--14], where most of the methodological work has focused on fully parametric
models without covariate adjustment. Developments under a semiparametric framework that incorporates covariate information
have been detailed in [15--19].
In this article, we develop a semiparametric Bayesian approach in the framework of cause-specific hazard function, where the
partial information about the cause of death is incorporated by means of latent variables. We propose to use a simulation-based
approach that exploits recent advances in Markov Chain Monte Carlo (MCMC) techniques, to implement the Bayesian methodology.
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The prior specifications follow standard practice in semiparametric Bayesian analysis. Section 2 describes the model formulation.
In Section 3 we present details of the Bayesian analysis, specifically prior models for the various parameters, and details of the
MCMC technique for posterior analyses. To illustrate our methodology, in Section 4 we present analyses of a cohort of breast
cancer cases from the Detroit SEER registry. A hybrid of Bayesian and frequentist methodology is used in the implementation
steps in order to obtain the estimates of model parameters. Finally, Section 5 contains some discussion and an appraisal of the
approach adopted in the current article in contrast to other approaches used in this context.
2. Model formulation
Earlier work in competing risks analysis utilized a series system (observing the minimum of several lifetimes) formulation in terms
of latent failure times. Tsiatis [20] warned about the identifiability issue that underlies such a formulation. Since then, substantial
efforts have been made to formulate a model that has direct links to the observables.
In order to understand the basics of a competing risks formulation under masked cause of death, we first need to lay down
some notational preliminaries. Suppose we have n subjects under study each of whom have J competing risks of death acting
on them. In what follows, let T , C denote the failure time and cause, respectively. One key ingredient in the competing risks
analysis is the cause-specific hazard defined as:
j(t)= lim
h−→0
Pr(tTt+h, C = j |Tt)
h
, j =1,. . . , J.
The corresponding cumulative incidence function is




where R(u)=Pr(Tu) is the overall survival function. The associated overall hazard rate (t)=−d log R(t) is related to the cause-
specific hazard rates by the equation (t)=∑Jj=1 j(t). Note that under the (non-testable) assumption of independence of the
risks, the series system formulation mentioned above is identifiable and in that case the cause-specific hazard j matches the
marginal hazard function associated with the jth latent lifetime random variable. In recent research on survival analysis with
masked cause of death, (1) has sometimes been used as a descriptor of the cause-specific nature of the framework [14].
Cause-specific hazard-based analysis and cumulative incidence function-based analysis are two alternative, albeit somewhat
different avenues of handling competing risks data. Fine and Gray [21] describe how the cause-specific regression formulation can
be turned into a regression model for cumulative incidence function via a complimentary log–log transformation. Many authors,
however, noted that despite this connection the co-variate effects based on one formulation can qualitatively be quite distinct
from that based on the other. Our strategy in this article is to focus on a single framework, namely the cause-specific formulation.
One can certainly develop a parallel Bayesian methodology under a regression setting for the cumulative incidence function.
We do not pursue this in the current article.
In the case of masked cause of death, the cause can be known up to a minimum random subset S⊂{1, 2,. . . , J} of the J risks.
Note that there are a total of 2J −1 possible such S’s. If the exact cause of death is known to be j, then S={j} is a singleton.
On the other extreme, if no knowledge is available on the cause of death, S={1,. . . , J}, resulting in full masking of the cause. For
each individual we observe the vector (T, S, X,), where X is the observed collection of covariate values for the individual, and
 is his/her censoring status (=1 if died, =0 if censored). Note that =0 would imply S={1,. . . , J}, by definition.
Throughout this article we assume that the censoring distribution (a) is independent of, and (b) does not share any parameter
with the overall survival distribution. In our context of studying death registry, this seems like a reasonable assumption. The joint
likelihood function of the observed data (Ti, Si, Xi,i)
n


















Given the knowledge of time and true cause of death, the masking probability qj(si; Xi, Ti)≡P(Si =si |Ti, Xi, Ci = j) signifies the
chance of the cause being masked by si . This quantity is difficult to handle as no natural estimate of it can be found based upon
the sampled data. Further, treating them as completely unspecified nuisance parameters gives rise to an over-parameterized
problem. A compromise adopted in the literature is the so-called ‘symmetry’ assumption that entails an equal chance of observing
the same masked subset of risk components irrespective of the true cause (within the masking subset) of death, i.e.
qj(si; Xi, Ti)=qj′ (si; Xi, Ti), j, j′ ∈si. (3)
In addition to the symmetry assumption, Guess et al. [22] and Lin et al. [23] further assumed q to be independent of T , X
and cited industrial examples where it was reasonable to make such assumptions. Dewanji and Sengupta [24] derived Nelson–
Aalen-type estimators of the cause-specific cumulative hazard functions for discrete survival data without assuming (3), but their
likelihood-based inference made explicit use of the symmetry assumption. Flehinger et al. [25, 26] avoided making the assumption





Copyright © 2010 John Wiley & Sons, Ltd. Statist. Med. 2010, 29 1681--1695
A. SEN ET AL.
pinpoint their true cause of death. In this article, we shall provide a Bayesian solution to the problem that does not need to rely
on any assumption such as (3) or any second-stage data. Further, we incorporate heterogeneity in the masking probabilities by
allowing them to depend on subject-level covariates.
Note that we shall work under the cause-specific formulation of (2), which precludes any a priori assumption of independence
among risks. In this sense, our solution can be thought of as an extension of Kuo and Yang [27]. Henceforth, for simplicity of
exposition, we shall suppress the argument for the q-probability and simply use appropriate indices to indicate its functional
dependence on relevant quantities.
For the cause-specific hazards, we choose the popular proportional hazards (PH) formulation, namely,
j(u, X)=0j(u) exp(′j X). (4)
Note here that 0j is the baseline hazard specific to cause j, and is allowed to vary across different causes. Similar comment
applies for the regression coefficient j . Also note that we use the entire collection X of covariates in formulating (4) merely for
the simplicity of exposition, and the set of predictors for different causes need by no means be identical.
3. Bayesian approach
In order to carry out the Bayesian analysis, we need to prescribe the prior models for various parameters.
3.1. Masking probabilities
Turning our attention to the masking probabilities first, we note that for a given (latent) cause of death C = j there are in all 2J−1
potential subsets S that would contain j. We shall explore two models for q’s that we describe below.
qDir: Here we model the vector of the masking probabilities as a Dirichlet random variable. More specifically,
qj(si; Xi, Ti)∼Dir2J−1 (j), j =1,. . . , J.
This model posits that the masking probabilities are independent of the death times as well as the covariate level. It is, of course,
possible to extend this model to the subject level, where the masking probabilities sharing the same latent cause j of death for
different subjects are viewed as independent random realizations from the above Dirichlet distribution. This is akin to a random
subject effect specification, and accounts for more model variation than a specification free of subject effect.
More specifically, given the (latent) true cause of death j, let sj ={sj1,. . . , sjk} denote the collection of potential subsets of causes
which contain j. Note that k is at most 2J−1. In this article, we entertain two sub-models in the class qDir. The first assumes
(qj(sj1),. . . , qj(sjk))∼Dirk(j), (5)
while the second formulation entails
(qij(sj1),. . . , qij(sjk))∼Dirk(j). (6)
In (5), the masking probabilities are identical for different subjects sharing the same underlying cause of death, drawn from the
Dirichlet distribution all at once. In contrast, under (6), the masking probabilities for different subjects sharing the same latent
cause of death are obtained using independent draws from the Dirichlet and hence are likely distinct.
qReg: As explained earlier, there is no natural empirical estimate for the masking probabilities. Thus, in order to borrow
strength indirectly from the auxiliary information, we assume a logistic regression model for the masking probabilities with
random regression coefficients. For the two-cause case, Lu and Tsiatis [19] and Tsiatis et al. [28] considered a similar regression
model, albeit under a frequentist framework. Further, they assumed a version of the symmetry assumption (3) which was required
for the large-sample inference to work.
3.2. Baseline hazard
In the PH framework, we can model the baseline hazard and the regression parameters separately. A common prior model for
the baseline hazard is the Gamma process popularized by Kalbfleisch [29]. Despite its limitations, it is used on a regular basis,
primarily due to its attractive statistical properties. We shall pursue two variants of the baseline hazard formulation in our case.
PB: The proportional baseline (PB) postulates the relation
0j(u)=0(u)pj, j =1,. . . , J,
where 0j is the cumulative baseline hazard for risk j, and 0 is a nonnegative, nondecreasing function common to all risks.
One important consequence of the PB model is the independence of the time and cause of death [30]. In this case, we assume
the prior specification
0(u) ∼ GP(c(u), c),
pj ∼ Gamma(j ,j), j=1,. . . , J,





A. SEN ET AL.
where all variables are assumed to be independent. In the Gamma process specification, the mean process (u) is viewed as
an initial estimate of 0, whereas c is a measure of degree of belief in the prior specification. Small values of c would reflect a
higher level of uncertainty about the prior specification, and vice versa.
NPB: Non-proportional baseline model (NPB) does not assume any relation between the cause-specific baselines. In this case,
we model each baseline as an independent Gamma process.
3.3. Regression coefficients
The regression coefficients are typically modeled as independent Normal or t variables, unless there is a priori reason to envision
them as skewed. In the latter case skew-normal or skew-t are reasonable prior choices for the  parameters. Also note that our
methodology allows complete flexibility to choose different distributions for the  parameters associated with the same covariate,
but different risks.
All group of parameters described above are further assumed to be stochastically independent. Elicitation of the prior parameters
has remained an inherent part of the prior selection process. Since a strong prior information can drive the direction of analysis in
a significant manner, it is imperative that reasonably accurate information on the prior parameters be obtained wherever possible.
In our context, one naive but often useful prior elicitation method may consist of extracting summary information (e.g. mean,
variance, percentile) on cause-specific survival from historical data or previous case studies and then translating the information
into parameter values for the prior distribution. In situations where such information is unavailable, one acceptable strategy is to
make the prior information sufficiently ‘diffused’ (by assuming a large variance), so that the effect of the prior on the end-analysis
is not over-bearing.
3.4. Posterior analysis
The posterior estimators of the various parameters are not in tractable form. We adopt the simulation-based MCMC technique
that relies on generating random draws from the relevant full conditional distributions in an iterative manner. The Bayesian
approach is greatly facilitated by data augmentation technique whereby exact cause of death Ci is imputed for the subject i for
whom the cause is missing. The imputation probabilities are easily calculated from (2) as
Pr(Ci = j |Xi, Si =si, Ti)=
qj(si; Xi, Ti)j(Ti, Xi)∑
j′∈si qj′ (si; Xi, Ti)j′ (Ti, Xi)
, j ∈si. (7)
Note that (7) has appeared in the literature under the name diagnostic probability [25, 26]. The full conditional distributions are
obtained from the likelihood augmented by the latent cause generated from (7).
3.5. Full conditionals
qj: In the case of Dirichlet prior for the masking probabilities, the full conditional distributions are also Dirichlet, whether the
modeling is at the subject-level or not. No such conjugacy obtains in the case of qreg model. It is important to note, however, that
either for the qdir or the qreg model, the full conditional distribution of the masking probabilities are stochastically independent
of those of the baseline intensity and the regression parameters .
Baseline: The full conditional distributions of the baseline cumulative intensities are in tractable form for the Gamma process
prior. They can be derived using straightforward adaptations of the representation in Kalbfleisch [29] to the competing risks case.







[Xlj +i I(Ci = j)Ulj],
where






The representation in the case with ties is more tedious, and will not be presented here. Note that the constants of proportionality
pj for the PB model have gamma full conditionals.
: The full conditionals for  are not in standard form. They are log-concave, however, if the corresponding priors are so
too. Log-concavity, while not essential to run the MCMC, certainly enhances its speed by enabling one to employ specialized
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4. Analysis of breast cancer data
4.1. Description of the data
We analyzed data from a cohort study of women newly diagnosed with breast cancer between January 1990 and December
1998 in the Detroit SEER catchment area. During this time frame a total of 10 620 women were diagnosed with breast cancer
in the Detroit SEER area. Survival for these women was measured from the time at diagnosis to time of last follow-up or death,
with a median follow-up of 13.2 years. For illustrative purposes, we analyze data from a sample of 500 women diagnosed with
local or regional stage breast cancer from this population.
In order to illustrate our methodology, we over-sampled the ‘masked’ cases from the original population so that our final
sample contains a sizable representation of the women with masked cause of death. Approximately 46 per cent of the women
in our analytic cohort died during the course of follow-up, either due to breast cancer, other cancer, or non-cancer related causes.
The exact cause of death was known for 56 per cent of these patients, with breast cancer and non-cancer causes largely contributing
to these deaths. The underlying cause of death was missing for the remaining group. Of these, however, partial information
was available on 35 per cent of the patients based on related cause of death fields reported in the state death certificate. This
resulted in masked survival data. Specifically, in this data set, 30 per cent of the women with missing cause of death had (breast
cancer, other cancer) as their masked (set) cause of death (for these patients the related cause of death fields listed other cancers
or ‘multiple cancers’), 5 per cent had (breast cancer, non-cancer) as their masked (set) cause of death (for these patients the
related cause of death fields listed ‘acute myocardial infarction’, ‘congestive heart failure’, ‘atherosclerosis’ etc.). In the original
population, only about 0.01 per cent of women had (other cancer, non-cancer) as their masked (set) cause of death. Therefore, we
dropped this small group of subjects from the sampling frame during sample selection, and further imposed model restrictions
that excludes such a masking group (specifics explained later). For 65 per cent of the women with missing cause of death, the
cause was completely masked (unknown, i.e. no additional information could be retrieved from the related cause of death fields).
Note that in this example we are dealing with three competing causes of death. All patients in the study were originally
diagnosed with breast cancer. Thus, breast cancer is the primary cause of interest (our ‘main’ cause). Death from other cancers
could either be related to the original breast cancer, or could be from independent diagnosis of some other cancer. Either way,
it is scientifically natural to group the other cancers together. Subsequently, all other (non-cancer) causes of death were lumped
in a single group. Breaking the non-cancer causes up in subgroups would have led to severe sparseness and have burdened the
model with further parameterization for no added scientific value.
4.2. Analytical framework
For the survival regression model, we considered as covariates race (African American vs Caucasian), stage (local or regional),
and age (in years) at diagnosis (continuous), all of which are well-established predictors of overall survival [32]. Table I shows the
distribution of the cause of death categories across the levels of the covariates. The distribution in the sample (Table I) is fairly
consistent with that in the original population.
For our analysis, we considered three models that are constructed using a combination of specifications described in Section 3.
The details are provided below.
Model 1: This model uses a PB formulation which induces a cause-specific hazard structure given by
j(u) = 0(u)pj exp(0j +1jAge+2jRace+3jStage), j =1,
= 0(u)pj exp(0j +1jAge+2jRace), j =2, 3,
where the indices j refer to the three causes of death, namely, breast cancer, other cancer and non-cancer related.
We further assume that the masking probabilities are specified by the Dirichlet distribution described as qDir specification of
(5) in Section 3. Note, however, that our prior specification excludes the masking subset (other cancer, non-cancer), so that
qBCa ∼Dir4(1,2,3,4), qOCa ∼Dir3(̃1, ̃2, ̃3), and qNCa ∼Dir3(̄1, ̄2, ̄3), where i , ̃i , ̄i are Dirichlet parameters chosen by
the analyst a priori.
Model 2: This model uses a nonrestrictive general baseline specification (NPB) for the cause-specific hazard functions. However,
the model still uses a Dirichlet specification for the masking probabilities, albeit at the subject level as in (6).
Model 3: In addition to the NPB hazard, this model also incorporates a regression structure for the masking probabilities.
The masking probabilities are modeled under a multinomial logistic framework with random regression coefficients. Denoting
by qij = (qij1, qij2,. . . , qijk) the k-dimensional vector of masking probabilities for the ith subject and jth cause, the multinomial






=′jlZi, l =1,. . . , k−1, j =1, 2, 3. (8)
Note that in (8), k refers to the number of potential masking subsets containing j, and hence, is at most 2J−1. In our example,
k equals 4 for BCa, and equals 3 for both OCa or NCa. Further, Zi is a vector describing individual i that may or may not have
an overlap with the vector of covariate levels Xi used to describe the cause-specific survival model. Also note that jl ’s are
allowed to differ between causes, ensuring further flexibility. Notwithstanding the capability and flexibility of the model above,
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Table I. Distribution of cause of death across levels of covariates∗.
Cause
Masked
BCa OCa NCa BCa/OCa BCa/NCa BCa/OCa/NCa Censored
Race (per cent AA) 29.1 6.7 7.3 16.1 20.0 14.5 14.8
Stage (per cent regional) 61.8 26.7 21.8 51.6 60.0 43.5 25.6
Mean age (Years) 59.3 67.3 75.6 64.8 61.6 65.7 57.9
(SD) (13.5) (11.8) (9.2) (13.4) (9.4) (13.6) (12.6)
∗BCa: breast cancer; OCa: other cancer; NCa: non-cancer.
it is difficult to identify useful predictors to be used in (8). This is due to the attempt to model a latent quantity on which
no information is available. In this article, we pursue this modeling primarily for illustrative purposes, and for comparing the
results with the other models. We report our findings based on a model that uses stage and dichotomized age (<65 years,
65 years) as covariates Zi in (8).
4.3. Prior parameterization
Dirichlet parameters: All Dirichlet parameters are taken to be equal to 1.
Gamma process parameters: The mean process (u) is taken to be proportional to u, i.e. (u)= ru, we assume c=0.01, r =0.5.
In this formulation, r is the proportionality constant attached to the mean function of the cumulative baseline hazard. An
alternative interpretation of r is that it is the mean of the baseline hazard rate which is constant by our choice of the functional
form. The quantity c on the other hand is the weight associated with guessing the baseline cumulative intensity to be equal
to its mean. Since c=E[] / Var[], the reciprocal of c can also be viewed as an over-dispersion factor. We have run our model
multiple times with small and large values of the over-dispersion factor with virtually identical estimates of the parameters. Of
course, if either r or c is too small, thereby making the prior information too negligible, convergence issues were encountered.
For our illustration, we further chose pj to be degenerate at 1, although a random pj specification such as the one mentioned
in Section 3 can easily be incorporated with a couple of additional lines of code.
Regression parameters: All regression parameters () for the survival model are assumed to be N(0, 106), the large standard
deviation (103) ensuring the prior specification to be diffused. The regression parameters () for Model 3 are assumed to be
N(0, 1), a specification that provided faster mixing.
4.4. Implementation
The analysis was carried out in WinBUGS version 1.4.1 [33] (sample code attached in the Appendix). In order to avoid computational
difficulties and facilitate faster convergence, we adopted a hybrid multiple imputation method. The steps followed for the posterior
calculations are detailed below.
Step 1: For each subject with masked cause of death, an exact (latent) cause of death was generated with equal probability
of selection for each eligible cause.
Step 2: For each model, MCMC was carried out (till convergence) to obtain posterior estimates of the model parameters using
the pseudo-complete data with the ‘imputed’ exact causes from step 1. For Models 1 and 2, the chains were run with a burn-in
of 2000 and thinning interval of 2. For Model 3, a burn-in of 4000 was used to provide a greater stabilization time. Posterior
characteristics were based on 2000 iterations. The summary statistics of the parameters were saved from the converged model.
Step 3: The cause of death for each subject with masked cause of death was redrawn using the imputation probabilities from
(7) and the estimates in Step 2.
Step 4: Steps 2 and 3 were repeated five times independently to generate five sets of estimates.
Step 5: The estimates were combined using Rubin’s formula [34] for multiple imputation. A normal distribution-based calculation
using the multiple imputation standard error is used to approximate the 95 per cent credible intervals.
The MCMC simulations were monitored using trace plots and other relevant diagnostics to ensure convergence. The cumulative
hazard plots and the barplots described later were generated in the general purpose statistical package R [35].
4.5. Results
Table II demonstrates the posterior summary statistics for the regression parameters. It is evident, based on the credible intervals,
that stage is a significant factor for breast cancer mortality. For all three models considered here, there is a significantly higher
(between 3.3 and 4.5 times greater on average) hazard of death for patients with regional stage cancer, compared with local
stage cancer. In our data, the African American women tend to have a higher hazard (between 1.3 and 1.5 times larger) of death
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Table II. Posterior mean, median and credible intervals for hazard ratios.
Breast cancer
Age Race (Ref: Caucasian) Stage (Ref: local)
Mean Median 95 per cent CI Mean Median 95 per cent CI Mean Median 95 per cent CI
Model 1 1.001 1.001 (0.982, 1.019) 1.528 1.539 (0.913, 2.558) 4.542 4.528 (2.672, 7.720)
Model 2 1.011 1.011 (0.993, 1.029) 1.354 1.361 (0.785, 2.333) 3.585 3.581 (2.291, 5.613)
Model 3 1.010 1.010 (0.994, 1.027) 1.490 1.499 (0.901, 2.465) 3.311 3.304 (2.103, 5.214)
Other Cancer
Model 1 1.048 1.048 (1.019, 1.078) 0.775 0.795 (0.249, 2.415)
Model 2 1.035 1.035 (1.013, 1.057) 1.306 1.319 (0.627, 2.718)
Model 3 1.033 1.033 (1.011, 1.055) 1.112 1.127 (0.536, 2.308)
Non Cancer
Model 1 1.123 1.122 (1.091, 1.155) 0.960 0.982 (0.394, 2.341)
Model 2 1.107 1.107 (1.079, 1.136) 0.712 0.730 (0.270, 1.882)
Model 3 1.112 1.112 (1.084, 1.140) 0.725 0.752 (0.297, 1.770)





























































Figure 1. Baseline Cumulative Hazard Plots for Model 2 (top) and Model 3 (bottom).
rendering the difference insignificant at 5 per cent level. While older women tended to show a slightly higher risk compared
with their younger counterparts, age did not turn out to be a significant predictor of breast cancer mortality. The posterior
distributions of all the regression coefficients turned out to be fairly symmetric.
For both other cancer and non-cancer related deaths, the picture is quite clear. Irrespective of the model used, for either
cause, age turns out to be the only significant predictor of death, with 3–5 per cent higher risk for other cancer, and 11–12
per cent higher risk for non-cancer related deaths for every one year increase in age.
Figure 1 shows the cumulative baseline hazard plots for the three causes under Model 2 and Model 3. Both plots, especially
the plot corresponding to Model 3, show indications confirming an NPB model. A formal model selection is carried out using
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Table III. Log-likelihood and DIC.
Posterior mean Log-likelihood at
log-likelihood posterior means DIC
Model 1 −1670.21 −1610.75 3459.36
Model 2 −1599.28 −1500.64 3395.86
Model 3 −1577.57 −1514.94 3280.39
the deviance information criterion (DIC) popularized by Spiegelhalter et al. [36]. The DIC values shown in Table III favor Model 3
slightly over the other two models.
It is of interest to investigate, for the subset of individuals with masked cause of death, the posterior likelihood of each (latent)
cause and how these change across the characteristic profile of the subject. These are precisely the ‘imputation’ probabilities
in (7). Figures 2 and 3 demonstrate these probabilities (expressed as percentages) for the subset of completely masked cases
stratified by race, stage, and age group. Each subplot is based on the mean of the posterior probabilities for the subset of
individuals falling in that classification category. The plots show the marked influence of the model used to compute these
probabilities. The discrepancy in diagnostic probabilities across models is more prominent for the subgroups which are sparsely
populated. For subgroups having a sizeable number of individuals, the diagnostic probabilities maintain the relative ranking
across all three models. It is also interesting to compare the probability distributions across profiles. For example, for a Caucasian
woman less than 65 years of age with regional stage cancer, there is a 58 per cent chance of breast cancer being the
primary cause of death (using Model 3). In comparison, for an individual with the same age and race, but local stage cancer,
the likelihood of breast cancer being the true (latent) cause of death is 28 per cent. For Caucasians older than 65 years,
on the other hand, other cancer and non-cancer related deaths are more likely to be the true cause of death. For African
American women older than 65 years, the inference may not be too reliable due to the small number of individuals in these
categories.
One interesting point to note here is that the posterior probabilities in Figures 2 and 3 are quite distinct from the observed
proportions for each cause in the same subgroups for the subjects with known cause of death. For example, for the subgroup of
Caucasians younger than 65 years diagnosed with local stage cancer (15 subjects), the proportions of deaths due to BCa, OCa,
and NCa, are 33.7, 25, and 41.7 per cent, respectively. Similarly, there is a 50-50 split between BCa and NCa as the observed
causes of death in the subgroup of Caucasian subjects who are 65 years or older and are diagnosed with regional stage cancer
(6 subjects). These are drastically different from the estimated posterior probabilities in the corresponding subgroups. This may
be construed as an indirect evidence that for our data set the imputation probabilities of (7) are strongly dependent on Si , the
masking subset of causes.
5. Concluding remarks
In this article, we have proposed a semi-parametric Bayesian approach to analyzing survival data with masked cause of death.
‘Masking’ is commonly encountered when analyzing data from large registries and population-based studies. The methods we
used to carry out the inference are quite similar to those in the missing data literature. Specifically, we used multiple imputation to
impute the propensity of a cause to be the primary reason for death when the actual cause of death is masked. The distribution
of these (latent) true causes is then used to create a ‘complete’ data set for carrying out the competing risks regression.
This process is carried out multiple times, and the estimates obtained from each pseudo-complete data set are combined using
the usual multiple-imputation formulas. Unlike in the usual missing data framework, however, the data-augmentation is carried
out in a Bayesian way.
To the extent we trust our model specification, our approach offers some flexibility in modeling. In the literature, competing
risks analysis with missing cause of death is often handled using either a symmetry structure on the q-probabilities, or
the availability of a second-stage data that are typically used to carry out likelihood-based inference. Based on a sample
run of our data using Model 1, for the subset of individuals with completely masked cause of death, we estimated the
full conditional distributions of the q-probabilities. There was substantial non-overlap between the probabilities. Specifically,
using 1, 2, 3 to denote breast cancer, other cancer, and non-cancer causes, respectively, the distribution of Pr(s={1, 2, 3} |
C =2, X) is completely separated from the distributions of Pr(s={1, 2, 3} |C =1, X) and Pr(s={1, 2, 3} |C =3, X), in violation of
the symmetry assumption. In the approach used in this article, we do not need to assume any symmetry structure on the
q-probabilities.
The Bayesian paradigm provides a unified framework for carrying out estimation and predictive inference. Further, it
lends itself readily to straightforward model selection procedures. The models we have used do not pre-suppose any
independence among the causes of death, and are valid for an arbitrary number of causes, thereby entertaining the
possibility of partial masking. By taking recourse to a simulation-based approach, we have avoided some complexities
of analytical inference. The possibility of entertaining a flexible modeling environment and the ease of implementa-
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White, >=65 years (n=11)
Model 3
Model 2












Breast Cancer Other Cancer Non Cancer
Black, >=65 years (n=4)
Model 3
Model 2
Model 145.6 25.3 29.1
49 50.8 0.2
74.8 24.8 0.3
Figure 2. Posterior probabilities (expressed as percentage) of the latent causes for the completely masked cause of death with regional stage cancer.
It is perhaps fair to put the modeling framework in proper perspective. While the Bayesian approach avoids the ‘symmetry’
assumption imposed on the masking probabilities, it puts a modeling structure (Dirichlet or logistic) on them. The symmetry
assumption implies missing at random mechanism that is un-testable based on observed data alone. While the Bayesian framework
does not need to rely on this mechanism, the parametric formulation of prior is equally un-testable and needs to be taken in
good faith.
One drawback of the approach presented here is the computation time. The semi-parametric Bayesian model involves generation
of random points from a stochastic process. The number of generations grows proportionately to the number of observations.
Consequently, the computing time becomes burdensome for a moderately large number of observations. For our data with 500
subjects, generation of a single MCMC chain consisting of 6000 realizations took between 7 and 8 h. In order to complete the
five chains for the multiple imputation, the computing time required was a little less than two days on a dedicated machine.
This feature, inherent in any simulation-based approach, counterbalances to some extent the flexibility and general applicability
of the methodology.
The model in (2) in its fully non-specified form is over-parameterized. Over-parameterization is not a formal technical problem
in Bayesian context since in this framework the parameters are assumed to be random draws from some distribution. Over-
parameterization can certainly lead to convergence issues in many situations, however. Part of the slow convergence rates we
encounter in our simulation is likely attributable to this reason.
Despite some of the shortcomings, the modeling approach seems to offer great promise in providing a flexible framework
for analyzing competing risks survival data with missing cause of death. Among individuals with a cancer diagnosis, one would
ideally like to estimate cause-specific mortality metrics in the presence of other causes of death. Such measures better reflect the
influence of cancer treatment interventions than all-cause survival, which can vary widely by race or other covariates of interest.
By employing a cause-specific framework in the presence of competing risks, one is able to assess the association of a covariate
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Breast Cancer Other Cancer Non Cancer
Black, >=65 years (n=3)
Model 3
Model 2
Model 117.2 38.3 44.6
24.7 39.3 35.9
33.1 30 36.9
Figure 3. Posterior probabilities (expressed as percentage) of the latent causes for the completely masked cause of death with local stage cancer.
with mortality from the primary cause of interest more reliably, unaffected by the association of this covariate with mortality
from other causes. The calculation of cause-specific mortality endpoints, such as time from diagnosis until death due to cancer
and the proportion of deaths attributable to the cancer, requires knowledge of the cause of death, which may only be partially
available in population data that rely on state death certificates. Other examples of missing cause of failure under competing
risks appear in areas such as reliability engineering. In this article, we have used our methodology to analyze data from the SEER
cancer registry, where the partial information about the cause of death is incorporated by means of latent variables.
The data analysis presented here serves only as an illustration of our methodology. In particular, we over-sampled the number
of patients with masked cause of death for illustrative purposes. This resulted in a non-random sampling from the original SEER
database. Therefore, based on our analysis, we cannot readily generalize our findings to the population of breast cancer patients.
However, in order to assess the effect of the non-random sampling on the inference, we ran a parallel competing risks analysis
in SAS 9.2 [37] following Lunn and McNeil [38] on all subjects in the entire database who are either censored or have a known
cause of death. Essentially the model is a stratified PH model with age, race, stage, and cause indicator as covariates. In order to
gauge the differential effects of age, race, stage across different causes, we also included interaction terms of these variables with
cause. Note that the stratified PH model differs from the Bayesian model proposed in this article in that the latter assumes the
same regression structure on all causes. Despite the above difference, this parallel analysis provides a comparison between the
results obtained using the entire data set and the sample used in the article. The point estimates of the hazard ratio for age are
1.008, 1.052, and 1.12, respectively, for BCa, OCa, and NCa, which are remarkably close to the corresponding posterior estimates
based on our Bayesian model. For BCa, the hazard ratio for race based on the stratified PH model is 1.6, which is quite close to
the estimate obtained from our Bayesian analysis. Frequentist estimate of the hazard ratio for stage with respect to breast cancer
mortality is 4.3, which is somewhat different in magnitude from the Bayesian estimate. Clearly, the confidence intervals obtained
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Bayesian analysis of the smaller sample. This resulted in a conclusion of significant racial difference for breast cancer mortality
based on the frequentist analysis of the larger data set which we failed to achieve in the smaller data set.
Appendix A
The following is the WinBUGS code for the competing risks model using Model 2. This assumes availability of a complete data
set with all known causes. The following notation is used in the code: N: number of subjects, T : number of distinct death times,
M: number of potential causes. There are two cause of death variables associated with each subject. One, labeled as cause[i]
for the ith subject, takes values 0, 1, 2, 3, denoting censoring or death due to BCa, OCa, NCa, respectively. These are a mix
of the observed and the estimated causes (for the ones whose exact cause of death is unknown). The observed subset of
causes is denoted by the variable S[i]. The vector obs.t contains observed times for all subjects, whereas Z’s represent covariate
information.
model {

















for (i in 1:N){
fail[i,1] <- equals(cause[i], 1)
fail[i,2] <- equals(cause[i], 2)


















for (i in 1:N){ for (j in 1:T){
Y[i,j] <- step(obs.t[i] - t[j] + eps)
for (k in 1:M){
dN[i,j,k] <- Y[i,j]*step(t[j+1] - obs.t[i] - eps)*fail[i,k] }
} }
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for (j in 1:T) {
for (i in 1:N) {
dN[i, j, 1] ~ dpois(Idt[i, j, 1]) Idt[i, j, 1] <-
Y[i,j]*exp(beta0[1] + beta1[1]*z1[i] + beta2[1]*z2[i] +
beta3*z3[i])*dL01[j]
}
for (i in 1:N) {
dN[i, j, 2] ~ dpois(Idt[i, j, 2])
Idt[i, j, 2] <- Y[i,j]*exp(beta0[2] + beta1[2]*z1[i] +
beta2[2]*z2[i])*dL02[j]
}
for (i in 1:N) {
dN[i, j, 3] ~ dpois(Idt[i, j, 3])
Idt[i, j, 3] <- Y[i,j]*exp(beta0[3] + beta1[3]*z1[i] +
beta2[3]*z2[i])*dL03[j]
}}
for (j in 1:T) {
dL01[j] ~ dgamma(mu[j,1], c)
dL02[j] ~ dgamma(mu[j,2], c)
dL03[j] ~ dgamma(mu[j,3], c)
for (k in 1:M) {
mu[j,k] <- dL0.star[j,k]*c
dL0.star[j,k] <- r[k]*(t[j+1] - t[j])
}
}
for (i in 1:N)
{
indi[i, cause[i] , 1:4] ~ dmulti(v[i, cause[i] , 1:4], 1)
}
for (i in 1:N)
{
v[i, 1, 1:4] ~ ddirch(alpha1[])
v[i, 2, 1:3] ~ ddirch(alpha2[])










for (k in 1:M)
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beta3 ~ dnorm(0.0,0.000001)
for (i in 1:N) {
q[i, 1, 1] <- v[i, 1,1]
q[i, 5, 1] <- v[i, 1,2]
q[i, 6, 1] <- v[i, 1,3]
q[i, 8, 1] <- v[i, 1,4]
q[i, 2,2] <- v[i, 2,1]
q[i, 5,2] <- v[i, 2,2]
q[i, 8,2] <- v[i, 2,3]
q[i, 3,3] <- v[i, 3,1]
q[i, 6,3] <- v[i, 3, 2]
q[i, 8,3] <- v[i, 3, 3]
}
for (i in 1:N)
{
u[i,1] <- exp(beta0[1] + beta1[1]*z1[i] + beta2[1]*z2[i] + beta3*z3[i])
*sumbase[i,1]
w[i,1] <- q[i,s[i],1]*exp(beta0[1] + beta1[1]*z1[i] + beta2[1]*z2[i] +
beta3*z3[i])*dL01[obstrank[i]]
u[i,2] <- exp(beta0[2] + beta1[2]*z1[i] + beta2[2]*z2[i])
*sumbase[i,2]
w[i,2] <- q[i,s[i],2]*exp(beta0[2] + beta1[2]*z1[i] + beta2[2]*z2[i] )
*dL02[obstrank[i]]
u[i,3] <- exp(beta0[3] + beta1[3]*z1[i] + beta2[3]*z2[i] )
*sumbase[i,3]




#If the subject is censored (s[i] = 4, then lik1=0 and only
# lik2 contributes (1st piece)
#If the subject is not censored, then the log-likelihood contribution
# is log(lik1)+lik2 (2nd piece)




#for those in subset (12)
#p11 = probablility of being cause = 1
for (i in (N1+1):N2){
p11[i] <- w[i,1] / (w[i,1] + w[i,2])}
#for those in subset (13)
#p21 = probability of being cause = 1
for (i in (N2+1):N3)
{
p21[i] <- w[i,1] / (w[i,1] + w[i,3])
}
#for those in subset (123)
#p41[,1] = probability of being cause = 1
#p42[,2] = probability of being cause = 2
#p43[,3] = probability of being cause = 3
for (i in (N4+1):N)
{
p41[i] <- w[i,1]/(w[i,1] + w[i,2] + w[i,3])
p42[i] <- w[i,2]/(w[i,1] + w[i,2] + w[i,3])
p43[i] <- 1 - p41[i] - p42[i]
}
}
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